| UniProt ID | TOE1_HUMAN | |
|---|---|---|
| UniProt AC | Q96GM8 | |
| Protein Name | Target of EGR1 protein 1 | |
| Gene Name | TOE1 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 510 | |
| Subcellular Localization | Nucleus, nucleolus . Nucleus speckle . Localizes to nuclear speckles. | |
| Protein Description | Inhibits cell growth rate and cell cycle. Induces CDKN1A expression as well as TGF-beta expression. Mediates the inhibitory growth effect of EGR1. Involved in the maturation of snRNAs and snRNA 3'-tail processing. [PubMed: 28092684] | |
| Protein Sequence | MAADSDDGAVSAPAASDGGVSKSTTSGEELVVQVPVVDVQSNNFKEMWPSLLLAIKTANFVAVDTELSGLGDRKSLLNQCIEERYKAVCHAARTRSILSLGLACFKRQPDKGEHSYLAQVFNLTLLCMEEYVIEPKSVQFLIQHGFNFNQQYAQGIPYHKGNDKGDESQSQSVRTLFLELIRARRPLVLHNGLIDLVFLYQNFYAHLPESLGTFTADLCEMFPAGIYDTKYAAEFHARFVASYLEYAFRKCERENGKQRAAGSPHLTLEFCNYPSSMRDHIDYRCCLPPATHRPHPTSICDNFSAYGWCPLGPQCPQSHDIDLIIDTDEAAAEDKRRRRRRREKRKRALLNLPGTQTSGEAKDGPPKKQVCGDSIKPEETEQEVAADETRNLPHSKQGNKNDLEMGIKAARPEIADRATSEVPGSQASPNPVPGDGLHRAGFDAFMTGYVMAYVEVSQGPQPCSSGPWLPECHNKVYLSGKAVPLTVAKSQFSRSSKAHNQKMKLTWGSS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Acetylation | ------MAADSDDGA ------CCCCCCCCC | 21.70 | 19413330 | |
| 5 | Phosphorylation | ---MAADSDDGAVSA ---CCCCCCCCCCCC | 32.64 | 29255136 | |
| 11 | Phosphorylation | DSDDGAVSAPAASDG CCCCCCCCCCCCCCC | 28.18 | 22167270 | |
| 16 | Phosphorylation | AVSAPAASDGGVSKS CCCCCCCCCCCCCCC | 38.60 | 23403867 | |
| 21 | Phosphorylation | AASDGGVSKSTTSGE CCCCCCCCCCCCCCC | 24.94 | 23403867 | |
| 33 | Ubiquitination | SGEELVVQVPVVDVQ CCCCEEEEEEEEECC | 26.73 | 22817900 | |
| 37 | Ubiquitination | LVVQVPVVDVQSNNF EEEEEEEEECCCCCH | 4.96 | 22817900 | |
| 74 | Ubiquitination | LSGLGDRKSLLNQCI CCCCCCHHHHHHHHH | 50.63 | 29967540 | |
| 75 | O-linked_Glycosylation | SGLGDRKSLLNQCIE CCCCCHHHHHHHHHH | 38.70 | 30379171 | |
| 84 | Ubiquitination | LNQCIEERYKAVCHA HHHHHHHHHHHHHHH | 26.01 | - | |
| 96 | Phosphorylation | CHAARTRSILSLGLA HHHHHHHHHHHHEEH | 27.54 | 28450419 | |
| 99 | Phosphorylation | ARTRSILSLGLACFK HHHHHHHHHEEHHHH | 20.79 | 28450419 | |
| 106 | Acetylation | SLGLACFKRQPDKGE HHEEHHHHCCCCCCC | 50.43 | 26051181 | |
| 114 | Ubiquitination | RQPDKGEHSYLAQVF CCCCCCCCCHHHHHH | 30.34 | 22817900 | |
| 118 | Ubiquitination | KGEHSYLAQVFNLTL CCCCCHHHHHHHHHE | 8.68 | 22817900 | |
| 160 | Ubiquitination | AQGIPYHKGNDKGDE HCCCCCCCCCCCCCH | 54.27 | 22817900 | |
| 164 | Acetylation | PYHKGNDKGDESQSQ CCCCCCCCCCHHHHH | 72.72 | 26051181 | |
| 164 | Ubiquitination | PYHKGNDKGDESQSQ CCCCCCCCCCHHHHH | 72.72 | 22817900 | |
| 166 | Ubiquitination | HKGNDKGDESQSQSV CCCCCCCCHHHHHHH | 59.10 | 22817900 | |
| 170 | Ubiquitination | DKGDESQSQSVRTLF CCCCHHHHHHHHHHH | 33.43 | 22817900 | |
| 354 | Ubiquitination | RALLNLPGTQTSGEA HHHHCCCCCCCCCCC | 33.35 | 22505724 | |
| 355 | Phosphorylation | ALLNLPGTQTSGEAK HHHCCCCCCCCCCCC | 27.08 | 21712546 | |
| 357 | Phosphorylation | LNLPGTQTSGEAKDG HCCCCCCCCCCCCCC | 38.24 | 25159151 | |
| 358 | Phosphorylation | NLPGTQTSGEAKDGP CCCCCCCCCCCCCCC | 25.48 | 25159151 | |
| 368 | Acetylation | AKDGPPKKQVCGDSI CCCCCCCCCCCCCCC | 54.45 | 26051181 | |
| 368 | Ubiquitination | AKDGPPKKQVCGDSI CCCCCCCCCCCCCCC | 54.45 | 29967540 | |
| 374 | Phosphorylation | KKQVCGDSIKPEETE CCCCCCCCCCHHHHH | 20.14 | 23312004 | |
| 376 | Acetylation | QVCGDSIKPEETEQE CCCCCCCCHHHHHHH | 50.78 | 26051181 | |
| 376 | Ubiquitination | QVCGDSIKPEETEQE CCCCCCCCHHHHHHH | 50.78 | 29967540 | |
| 401 | Ubiquitination | HSKQGNKNDLEMGIK HHCCCCHHHHHHHHH | 64.20 | - | |
| 419 | Phosphorylation | PEIADRATSEVPGSQ HHHHHHCCCCCCCCC | 26.72 | 29255136 | |
| 420 | Phosphorylation | EIADRATSEVPGSQA HHHHHCCCCCCCCCC | 35.30 | 30266825 | |
| 425 | Phosphorylation | ATSEVPGSQASPNPV CCCCCCCCCCCCCCC | 19.26 | 23401153 | |
| 428 | Phosphorylation | EVPGSQASPNPVPGD CCCCCCCCCCCCCCC | 19.99 | 23401153 | |
| 435 | Ubiquitination | SPNPVPGDGLHRAGF CCCCCCCCCCCCCCC | 50.87 | 22505724 | |
| 481 | Acetylation | NKVYLSGKAVPLTVA CEEEECCCEEECCHH | 42.72 | 26051181 | |
| 481 | Ubiquitination | NKVYLSGKAVPLTVA CEEEECCCEEECCHH | 42.72 | 22505724 | |
| 487 | Ubiquitination | GKAVPLTVAKSQFSR CCEEECCHHHHHHCC | 9.22 | 22505724 | |
| 489 | Ubiquitination | AVPLTVAKSQFSRSS EEECCHHHHHHCCCC | 40.22 | 29967540 | |
| 509 | Phosphorylation | KMKLTWGSS------ CCCCEECCC------ | 25.16 | 21712546 | |
| 510 | Phosphorylation | MKLTWGSS------- CCCEECCC------- | 40.06 | 22617229 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of TOE1_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of TOE1_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of TOE1_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| APLP1_HUMAN | APLP1 | physical | 16169070 | |
| SUMO1_HUMAN | SUMO1 | physical | 16169070 | |
| RS3A_HUMAN | RPS3A | physical | 16169070 | |
| SH3G3_HUMAN | SH3GL3 | physical | 16169070 | |
| PYM1_HUMAN | WIBG | physical | 22939629 | |
| SF3B2_HUMAN | SF3B2 | physical | 22365833 | |
| SF3B3_HUMAN | SF3B3 | physical | 22365833 | |
| U2AF1_HUMAN | U2AF1 | physical | 22365833 | |
| RBM39_HUMAN | RBM39 | physical | 22365833 | |
| SRSF6_HUMAN | SRSF6 | physical | 22365833 | |
| LSM4_HUMAN | LSM4 | physical | 22365833 | |
| PRCC_HUMAN | PRCC | physical | 22365833 | |
| RED_HUMAN | IK | physical | 22365833 | |
| RBM8A_HUMAN | RBM8A | physical | 22365833 | |
| WDR83_HUMAN | WDR83 | physical | 22365833 | |
| PP1A_HUMAN | PPP1CA | physical | 22365833 | |
| AGGF1_HUMAN | AGGF1 | physical | 22365833 | |
| MEP50_HUMAN | WDR77 | physical | 22365833 | |
| HNRPF_HUMAN | HNRNPF | physical | 22365833 | |
| IL7RA_HUMAN | IL7R | physical | 23151878 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT SER-5, AND MASS SPECTROMETRY. | |
| Phosphorylation | |
| Reference | PubMed |
| "Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5, AND MASSSPECTROMETRY. | |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT SER-5, AND MASS SPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5, AND MASSSPECTROMETRY. | |
| "Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis."; Wang B., Malik R., Nigg E.A., Korner R.; Anal. Chem. 80:9526-9533(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5, AND MASSSPECTROMETRY. | |
| "Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5, AND MASSSPECTROMETRY. | |